Czechia· CZ-0210115
SYNAGIS
A palivizumab product containing palivizumab, registered in Czechia by AstraZeneca AB, Södertälje. The same ATC class is registered in 13 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Palivizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC J06BD01 (palivizumab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 9 of them publish a price we can compare per daily dose
Palivizumab · ATC J06BD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of palivizumab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Palivizumab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$51.40
The record
At a glance
SÚKL (Czech Republic)- Active substance
- PALIVIZUMAB
- Manufacturer
- AstraZeneca AB, Södertälje
- Country
- Czechia (CZ)
- ATC code
- J06BD01
- ATC class
- Palivizumab
- Defined daily dose
- 3.75 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02101151X1MLCZK 21185.86
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwaySynagisAstraZeneca
- SwitzerlandSynagis 100 mg/1 ml, InjektionslösungAstraZeneca AG
- SpainSYNAGIS 100 mg/1 ml SOLUCION INYECTABLEAstrazeneca Ab
- BelgiumSynagis 100 mg/mlAstraZeneca
- SwedenSynagis 100 mg/1 ml Injektionsvätska, lösningAstraZeneca AB
- IcelandSynagisAstraZeneca AB*
- PolandSynagisAstraZeneca AB
- FinlandSynagisOrifarm Oy
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Synagis
- Liechtenstein · Synagis
- Norway · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e31b1206-71cd-437b-9b68-872edf9f9102 GET /v1/drugs/e31b1206-71cd-437b-9b68-872edf9f9102?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL",
"source": "sukl",
"strength": "100MG/1ML",
"pack_size": "1X1ML",
"substance": "PALIVIZUMAB",
"cz_kod_sukl": "0210115",
"product_type": "BT",
"substance_codes": "14990",
"registration_state": "R",
"registration_number": "EU/1/99/117/004"
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.